

# Lumakras Drug Clinical Insight & Sales Forecast 2026

<https://marketpublishers.com/r/LE9EFC8162E8EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: LE9EFC8162E8EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Lumakras Drug Clinical Insight & Sales Forecast 2026” Report Highlights:

NSCLC Targeting Lumakras Market Opportunity (US\$ Million)

Colorectal Cancer Targeting Lumakras Market Opportunity (US\$ Million)

Pharmacokinetics of Lumakras (Sotorasib)

Dosage, Patent & Price Analysis

Lumakras Ongoing Clinical Trials

Global KRAS Protein Inhibitors Clinical Trials

The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management of cancer. Despite huge advancements in the field of cancer therapeutics, there has been no permanent cure of cancer till now. However, the advancement in the field of science and technology has led to the identification of potential targets which can be utilized in drug development process.

The identification of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene as well as its potential role in the pathogenesis and proliferation of cancer has shown to be boon in cancer therapeutics. The extensive research and development by the researchers has led to the discovery of novel KRAS inhibitors which are used in the

management of rare ALK positive cancers. Till now, only one KRAS inhibitor has been approved for the management of non-small cell lung cancer.

Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen and was approved by FDA in May, 2021. Lumakras is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. The approval of Lumakras represents as one of the major revolution in the field of cancer treatment.

Owing to their favorable characteristics in management of NSCLC as well its high specificity and efficacy, it is expected that Lumakras market will witness high growth rates. As per report findings, it is expected that Lumakras market is expected to surpass US\$ 1.5 Billion by 2026. This is due to the ability of Lumakras in overcoming the limitations of already conventional cancer therapies. Moreover, the drug Lumakras is not associated with side effects in comparison to conventional cancer treatments and also improved the survival rates in patients.

Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years. However, increasing initiatives by government and the pharmaceutical companies for the development of favorable reimbursement policies will help in lowering the cost of the therapy, thus reducing financial toxicity on patients.

The global Lumakras market will follow trajectory path during the forecast period owing to the single product approval. In addition to this, researchers are also evaluating the role of Lumakras in other solid tumors as well in combination of other immunotherapeutic drugs, which will drive the growth of market. North America particularly US is expected to dominate the global Lumakras market for next few years owing to increase in prevalence of non-small cell lung cancer and the presence of large pharmaceutical companies which actively indulge in research and development activities.

The report global Lumakras market contains information on the price, dosage and expected sales of the drug in different regions. In addition to this, it also provides information on the safety, efficacy, pharmacokinetics, and pharmacovigilance profile of Lumakras. The report also provides insights on the recent clinical trials undergoing with

the drug and predict the future market of the drug at a global level.

## Contents

### **1. LUMAKRAS (SOTORASIB) - FIRST APPROVED KRAS INHIBITOR DRUG**

- 1.1 Market Overview
- 1.2 Future Opportunity

### **2. LUMAKRAS - MECHANISM OF ACTION**

### **3. LUMAKRAS - STRUCTURE, DESCRIPTION & PHARMACOKINETICS**

- 3.1 Chemistry & Physical Properties
- 3.2 Pharmacokinetics

### **4. ROLE OF LUMAKRAS IN NSCLC**

### **5. ROLE IN LUMAKRAS IN SOLID TUMORS**

### **6. LUMAKRAS - COMMERCIAL ASPECTS**

- 6.1 Overview & Patent Insight
- 6.2 Dosage & Price Analysis

### **7. LUMAKRAS - SUPPLEMENTARY INFORMATION**

- 7.1 Adverse Drug Reactions
- 7.2 Drug Interaction
  - 7.2.1 Effects of Other Drugs on Lumakras
  - 7.2.2 Effects of Lumakras on Other Drugs

### **8. LUMAKRAS ONGOING CLINICAL TRIALS**

- 8.1 Global KRAS Protein Inhibitors Clinical Trials
- 8.2 Global Lumakras Clinical Trials

### **9. CLINICAL DEVELOPMENT TRENDS BY REGIONS**

- 9.1 US

## 9.2 Rest of World

# 10. COMPANIES INVOLVED IN DEVELOPMENT OF KRAS INHIBITORS

- 10.1 Amgen
- 10.2 Boehringer Ingelheim
- 10.3 Codiak Biosciences
- 10.4 Cotinga Pharmaceuticals
- 10.5 Eli Lilly
- 10.6 Gilead
- 10.7 Johnson & Johnson
- 10.8 Mirati Therapeutics
- 10.9 Merck
- 10.10 Moderna
- 10.11 Oblique Therapeutics
- 10.12 Revolution Medicines
- 10.13 Silenseed

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Global – Frequency of KRAS G12C Mutation by Cancer Type (%), 2021 & 2026

Figure 1-2: Global – KRAS Mutation by Type (%), 2020

Figure 1-3: Global – Estimated KRAS Mutated NSCLC Population for KRAS Inhibitors, 2021 & 2026

Figure 1-4: Global – NSCLC Targeting Lumakras Market Opportunity by 5% of Targeted Population (US\$ Million), 2021 - 2026

Figure 1-5: Global – NSCLC Targeting Lumakras Market Opportunity by 10% of Targeted Population (US\$ Million), 2021 - 2026

Figure 1-6: Global – NSCLC Targeting Lumakras Market Opportunity by 15% of Targeted Population (US\$ Million), 2021 - 2026

Figure 1-7: Global – NSCLC Targeting Lumakras Market Opportunity by 20% Targeted Population (US\$ Billion), 2021 - 2026

Figure 1-8: Global – NSCLC Targeting Lumakras Market Opportunity by 25% Targeted Population (US\$ Billion), 2021 - 2026

Figure 1-9: Global – Estimated KRAS G12C Mutated Colorectal Cancer Population for KRAS Inhibitors, 2021 & 2026

Figure 1-10: Global – Colorectal Cancer Targeting Lumakras Market Opportunity by 5% of Targeted Population (US\$ Million), 2021 - 2026

Figure 1-11: Global – Colorectal Cancer Targeting Lumakras Market Opportunity by 10% of Targeted Population (US\$ Billion), 2021 - 2026

Figure 1-12: Global – Colorectal Cancer Targeting Lumakras Market Opportunity by 15% of Targeted Population (US\$ Million), 2021 - 2026

Figure 1-13: Global – Colorectal Cancer Targeting Lumakras Market Opportunity by 20% Targeted Population (US\$ Billion), 2021 - 2026

Figure 1-14: Global – Colorectal Cancer Targeting Lumakras Market Opportunity by 25% Targeted Population (US\$ Billion), 2021 - 2026

Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer

Figure 2-2: Targeting Approaches of KRAS Inhibitors

Figure 2-3: Mechanism of Lumakras - Direct Targeting of Mutant KRAS

Figure 3-1: Structure of Lumakras

Figure 4-1: Global – Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020

Figure 4-2: Global – Lung Cancer Incidence by Type (%), 2020

Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer

Figure 5-1: Global – Frequency of Overall KRAS Mutation & KRAS G12C Mutation (%)

Figure 6-1: Lumakras – FDA Approval & Patent Expiration Year

Figure 6-2: Lumakras – Price for 240 Tablet Supply & Price Per Unit of 120mg Tablet (US\$), July'2021

Figure 6-3: Lumakras – Monthly & Annual Treatment Cost (US\$), July'2021

Figure 6-4: Lumakras – Recommended Initial & Reduced Dose (mg/day)

Figure 7-1: Lumakras – List of Adverse Events

Figure 8-1: Global - KRAS Protein Inhibitors Clinical Trials by Phase, 2020 -2026

Figure 8-2: Global - KRAS Protein Inhibitors Clinical Trials by Country, 2020 -2026

Figure 8-3: Global - KRAS Protein Inhibitors Clinical Trials by Company, 2020 -2026

Figure 8-4: Global - KRAS Protein Inhibitors Clinical Trials by Indication, 2020 -2026

Figure 8-5: Global - KRAS Protein Inhibitors Clinical Trials by Patient Segment, 2020 -2026

Figure 8-6: Global – Number of KRAS G12C Inhibitors in Clinical Trial by Phase, July 2021

Figure 8-7: Global – KRAS G12C Inhibitors in Clinical Trial by Phase (%), July 2021

Figure 8-8: Codebreak 200 Trial – Study Initiation & Expected Completion Year

Figure 8-9: Codebreak 105 Trial – Study Initiation & Expected Completion Year

Figure 8-10: Codebreak 101 Trial – Study Initiation & Expected Completion Year

## I would like to order

Product name: Lumakras Drug Clinical Insight & Sales Forecast 2026

Product link: <https://marketpublishers.com/r/LE9EFC8162E8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LE9EFC8162E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970